Get the Stockscreener App
101.01
0.11%
0.11
Pre-market:
100.70
-0.31
-0.31%
Exact Sciences Corp stock is traded at $101.01, with a volume of 14.48M.
It is up +0.11% in the last 24 hours and up +56.27% over the past month.
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
See More
Previous Close:
$100.90
Open:
$100.92
24h Volume:
14.48M
Relative Volume:
3.38
Market Cap:
$19.14B
Revenue:
$2.83B
Net Income/Loss:
$-1.02B
P/E Ratio:
-18.33
EPS:
-5.51
Net Cash Flow:
$194.14M
1W Performance:
+50.42%
1M Performance:
+56.27%
6M Performance:
+77.37%
1Y Performance:
+90.91%
1-Day Range:
$100.92
$101.26
1-Week Range:
$66.00
$101.87
52-Week Range:
$38.81
$101.87
Exact Sciences Corp Stock (EXAS) Company Profile
Name
Exact Sciences Corp
Sector
Industry
Phone
608-284-5700
Address
5505 ENDEAVOR LANE, MADISON, WI
Compare EXAS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EXAS
Exact Sciences Corp
|
101.01 | 19.15B | 2.83B | -1.02B | 194.14M | -5.51 |
|
TMO
Thermo Fisher Scientific Inc
|
586.07 | 220.72B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
226.98 | 160.62B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
752.14 | 57.96B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
153.60 | 42.88B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
228.18 | 38.30B | 15.90B | 1.28B | 2.21B | 7.2842 |
Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Mar-13-25 | Initiated | RBC Capital Mkts | Sector Perform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-27-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Jan-02-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Oct-10-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Aug-02-23 | Downgrade | The Benchmark Company | Buy → Hold |
| May-10-23 | Upgrade | Craig Hallum | Hold → Buy |
| May-05-23 | Initiated | UBS | Neutral |
| Mar-09-23 | Upgrade | Citigroup | Neutral → Buy |
| Feb-10-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jan-18-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Oct-19-22 | Downgrade | Craig Hallum | Buy → Hold |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jun-03-22 | Initiated | Piper Sandler | Neutral |
| Nov-03-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jul-29-21 | Reiterated | BTIG Research | Buy |
| Jul-29-21 | Reiterated | Canaccord Genuity | Buy |
| Jul-29-21 | Reiterated | Oppenheimer | Outperform |
| Jul-29-21 | Reiterated | Stifel | Buy |
| Jun-15-21 | Initiated | Raymond James | Strong Buy |
| Jun-03-21 | Initiated | Goldman | Buy |
| May-25-21 | Initiated | Wells Fargo | Equal Weight |
| Jan-28-21 | Initiated | Truist | Buy |
| Oct-29-20 | Downgrade | UBS | Buy → Neutral |
| Oct-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Oct-08-20 | Resumed | BTIG Research | Buy |
| Apr-02-20 | Initiated | Evercore ISI | Outperform |
| Jan-10-20 | Resumed | BTIG Research | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Dec-13-19 | Initiated | Dougherty & Company | Buy |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-17-19 | Reiterated | BofA/Merrill | Buy |
| Oct-01-19 | Resumed | Craig Hallum | Buy |
| Sep-26-19 | Initiated | Oppenheimer | Outperform |
| Feb-26-19 | Upgrade | Goldman | Neutral → Buy |
| Oct-09-18 | Initiated | UBS | Buy |
| Sep-05-18 | Resumed | The Benchmark Company | Hold |
| Aug-13-18 | Reiterated | Canaccord Genuity | Buy |
| Apr-03-18 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-29-18 | Initiated | Goldman | Neutral |
| Jan-08-18 | Reiterated | The Benchmark Company | Buy |
| Nov-13-17 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-01-17 | Downgrade | BTIG Research | Buy → Neutral |
View All
Exact Sciences Corp Stock (EXAS) Latest News
Halper Sadeh LLC Encourages GDOT, BLFY, EXAS Shareholders to Contact the Firm to Discuss Their Rights - Finviz
Exact Sciences stock rating downgraded to Hold by TD Cowen following Abbott deal - Investing.com
Canaccord Genuity downgrades Exact Sciences stock to Hold after Abbott deal - Investing.com
Exact Sciences Reinforces International Leadership in Breast Cancer with Strong Presence at 2025 San Antonio Breast Cancer Symposium - Markets Financial Content
UBS raises Exact Sciences stock price target to $105 on Abbott deal - Investing.com
Abbott is buying Exact Sciences. Here’s why - Modern Healthcare
Exact Sciences (EXAS) Downgraded to Hold by Benchmark Analyst | EXAS Stock News - GuruFocus
Here are Monday’s Top Wall Street Analyst Research Calls: Baidu, Carvana, Exact Sciences, Ferrari, Marvell Technology, Meta Platforms and More - MSN
Exact Sciences (EXAS) Receives Downgrade from Jefferies Amidst P - GuruFocus
Here are Monday's Top Wall Street Analyst Research Calls: Baidu, Carvana, Exact Sciences, Ferrari, Marvell Technology, Meta Platforms and More - 24/7 Wall St.
This Argenx Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga
Jefferies downgrades Exact Sciences stock to Hold after Abbott acquisition - Investing.com
Jim Cramer on Abbott: “I Think It’s a Terrific Time to Do Some Buying” - Yahoo! Finance Canada
Exact Sciences Stock Falls Premarket Despite Wall Street Calling For A Triple-Digit Abbott Takeover - MSN
Q3 Earnings Highs And Lows: Exact Sciences (NASDAQ:EXAS) Vs The Rest Of The Immuno-Oncology Stocks - Finviz
Abbott’s (ABT) Exact Sciences Deal is “Very, Very Important,” Says Jim Cramer - Insider Monkey
Halper Sadeh LLC Encourages EXAS, NVRI, MRUS Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire Inc.
Exact Sciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Exact Sciences CorporationEXAS - Barchart.com
Analysts Are Bullish on These Healthcare Stocks: Nano-X Imaging (NNOX), Exact Sciences (EXAS) - The Globe and Mail
Exact Sciences Corp Executives Engage in Stock Transactions - TradingView
[Form 4] EXACT SCIENCES CORP Insider Trading Activity - Stock Titan
VP Orville Sells 5,000 ($375K) Of Exact Sciences Corp [EXAS] - TradingView
Exact Sciences Stock Soars To 4-Year High Even As Wall Street Piles On Downgrades After Abbott Deal — Retail Traders Take Profits - MSN
EXASExact Sciences Corp Stock Price and Quote - Finviz
Exact Sciences likely needs to see over $100/share in takeoveranalyst - MSN
Deal Dispatch: Abbott, TPG And Lonza Make Major Moves, M&M Custard And New Fortress Energy Struggle - Benzinga
Exact Sciences (EXAS): Wells Fargo Downgrades Rating, Raises Pri - GuruFocus
Abbott Laboratories to acquire Exact Sciences for $23B in largest-ever diagnostics deal - The Business Journals
Exact Sciences (EXAS) Receives Downgrade from William Blair | EX - GuruFocus
Abbott Labs stock to acquire Exact Sciences for $21 billion - Investing.com
Abbott Labs stock to acquire Exact Sciences for $21 billion By Investing.com - Investing.com UK
Exact Sciences (EXAS) Downgraded to Neutral by Guggenheim | EXAS Stock News - GuruFocus
EXAS: Barclays Downgrades Exact Sciences, Raises Price Target to $105 | EXAS Stock News - GuruFocus
Here Are Friday’s Top Wall Street Analysts Research Calls: Advanced Micro Devices, Block, Broadcom, Exact Sciences, Hologic, Palo Alto Networks and More - Yahoo Finance
Abbott Labs stock gains as UBS reiterates Buy rating on Exact Sciences deal - Investing.com
Here Are Friday's Top Wall Street Analysts Research Calls: Advanced Micro Devices, Block, Broadcom, Exact Sciences, Hologic, Palo Alto Networks and More - 24/7 Wall St.
Exact Sciences joins Abbott, shares soar 18% on acquisition and growth prospects - Mugglehead Magazine
Abbott Eyes Exact Sciences: Market Stir - StocksToTrade
Halper Sadeh LLC Encourages CIVI, JAMF, EXAS Shareholders to Contact the Firm to Discuss Their Rights - Finviz
Exact Sciences, Leader in Cancer Screening and Genomics Testing, to Join Abbott Laboratories in 2026 - Morningstar
Why the Stock Price of This Cancer Screening Company Soared 17% Thursday - MSN
Abbott Laboratories $23B purchase of Cologuard maker Exact Sciences could have Arizona implications - The Business Journals
Abbott to Buy Cancer-Screener Exact Sciences for $21 Billion - MSN
Why Exact Sciences Stock Surged Today - Finviz
Abbott Laboratories to acquire Exact Sciences in deal worth up to $23B - The Business Journals
Why Exact Sciences Rallied Over 50% This Week - Nasdaq
Exact Sciences Stock Pops on $21 Billion Deal. Is It Too Late to Buy EXAS Here? - Yahoo Finance
Abbott Laboratories, Exact Sciences make $23B deal with Bay Area implicationsSan Francisco Business Times - The Business Journals
EXAS Shares Soar Amid Acquisition Rumors - timothysykes.com
Top Stock Movers Now: Walmart, Nvidia, Exact Sciences, Bath and Body Works, and More - Investopedia
Exact Sciences (EXAS) Soars Over 17% in Stock Market Surge - GuruFocus
Exact Sciences Corp Stock (EXAS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.35%
1.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):